Applied Clinical Trials-02-01-2009

Applied Clinical Trials
View from Brussels

February 01, 2009

What to expect from the new leadership and why there's not much hope for an improved directive.

Applied Clinical Trials
Feature Article

February 01, 2009

A look into the evolving relationship and what motivates the two to work together.

Applied Clinical Trials
Feature Article

February 01, 2009

Concerns are being put into action with the trend toward better investigator training.

Applied Clinical Trials

February 01, 2009

S

Applied Clinical Trials
Business News

February 01, 2009

Industry news focusing on the people and organizations who work in the clinical trials profession.

Applied Clinical Trials
Global News

February 01, 2009

Bridging studies help pave the way for more efficient global drug development in the Asia-Pacific region.

Applied Clinical Trials
Feature Article

February 01, 2009

Global clinical trial landscape changes pose new challenges for all sites-even AMCs.

Applied Clinical Trials
Feature Article

February 01, 2009

How the merging of medical faculty and academic hospitals in The Netherlands is improving the country's research infrastructure.

Applied Clinical Trials
A Closing Thought

February 01, 2009

Ways to ensure the transition between vendors is as smooth as possible for everyone involved.

Applied Clinical Trials
Feature Article

February 01, 2009

Perspectives on adoption of technology at U.S. Academic Medical Centers and how sponsors will be impacted.

Applied Clinical Trials
eShowcase

February 01, 2009

The latest eclinical software in the clinical trials industry.

News
Applied Clinical Trials

February 01, 2009

Clearing up the misunderstandings that often arise when bringing a product combining a dietary supplement and prescription drug to market.

Applied Clinical Trials
Technology Viewpoint

February 01, 2009

Can processes used for 20 years in the manufacturing and retail industries work for us too?

View from Washington
Applied Clinical Trials

February 01, 2009

Proposals to reduce outlays for drugs could limit biomedical research and product development.